AnaptysBio, Inc. ANAB Business Segments
| Q1 '26 | Q4 '25 | Q3 '25 | Q2 '25 | Q1 '25 | ||
|---|---|---|---|---|---|---|
| Revenue by Business | ||||||
| Biopharma Company | $0— | —— | —— | —— | $0— | |
| Royalty Management Company | $25.56M-8.0% | —— | —— | —— | $27.77M+21.7% | |
| Revenue by Product | ||||||
| Anaptys Bio Generated Anti PD1Jemperli Dostarlimab | $258M— | $75M+200% | $50M+233% | $133M— | $0-100% | |
| License | $0-100% | $0— | $0— | $0— | $9.6M— | |
| Transaction Service | $100K0.0% | —— | $100K— | $100K— | $100K— |
Chart any of these lines over time, or line them up against competitors.
Compare these in charts →Questions, answered.
- How does AnaptysBio, Inc. break its business down?
- AnaptysBio, Inc. (ANAB) reports revenue by business across 2 parts — Biopharma Company and Royalty Management Company. Each is extracted from the segment footnotes and tracked over time.
- Where does AnaptysBio, Inc.'s segment data come from?
- Segment breakdowns are pulled from the segment footnotes in AnaptysBio, Inc.'s SEC filings (the XBRL dimensional tags), so every line ties back to a reported figure. Switch between quarterly, annual, and TTM, or open any segment for its full history.
